Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JU.0000000000003704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[En bloc transurethral resection for non-muscle invasive bladder cancer].
Urologiia
May 2024
FGBU Central state medical academy of Administrative Directorate of the President of Russian Federation, Moscow, Russia.
Bladder cancer (BC) is a severe, and in some cases disabling disease for which no active detection strategy has been developed. It requires careful differential diagnosis, and is associated with a high risk for recurrence and progression. The choice of optimal treatment of non-muscle-invasive bladder Cancer (NMIBC) can reduce the rate of recurrence and improve oncologic outcomes.
View Article and Find Full Text PDFRole of repeat transurethral resection in no-muscle-invasive bladder tumour: an umbrella review.
Ther Adv Med Oncol
November 2024
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu, Sichuan Province, 610041, China.
Background: Repeat transurethral resection of bladder tumour (reTURB) is a conventional treatment for non-muscle-invasive bladder cancer (NMIBC) to enhance prognosis. However, the necessity of reTURB in NMIBC remains controversial owing to upstaging of treatments and new evidence.
Objectives: We performed an umbrella review to determine the need for reTURB in patients with NMIBC.
Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study.
BJUI Compass
November 2024
British Urology Researchers in Surgical Training (BURST) London UK.
Objective: The objective of this study was to report the 12-month oncological outcomes for patients with non-muscle-invasive bladder cancer (NMIBC) within the prospective, international COVIDSurg Cancer study.
Patients And Methods: Eligible patients were aged ≥18 years and scheduled for elective surgical management of NMIBC with curative intent (transurethral resection of bladder tumour [TURBT] or bladder biopsy) from 21 January to 14 April 2020. The primary outcome was disease recurrence within 12 months of previous elective TURBT/bladder biopsy.
Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients.
Ann Surg Oncol
January 2025
Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Background: Bladder cancer (BCa) diagnosis relies on distinguishing muscle-invasive bladder cancer (MIBC) from non-muscle-invasive bladder cancer (NMIBC) forms. Transurethral resection of the bladder tumor (TURBT) is a standard procedure for initial staging and treatment. The Vesical Imaging-Reporting and Data System (VI-RADS) enhances diagnostic accuracy for muscle invasiveness through advanced imaging techniques, potentially reducing reliance on repeat TURBT and improving patient management.
View Article and Find Full Text PDFEn Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis of Oncological, Histopathological, and Surgical Outcomes.
Eur Urol Oncol
October 2024
Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group.
Article Synopsis
- En bloc resection of bladder tumor (ERBT) is a surgical technique aimed at improving bladder cancer removal compared to conventional transurethral resection (cTURBT), focusing on perioperative and cancer-related outcomes.
- A review of 17 studies found no significant differences in cancer recurrence or progression rates between ERBT and cTURBT, although ERBT was linked to better detection of detrusor muscle (DM) presence, and lower risks of bladder perforation and obturator nerve reflexes.
- ERBT resulted in longer surgery times but shorter catheterization and hospital stays, indicating a safer approach overall, despite the lack of major differences in long-term cancer outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!